Can cheaper drugs help home-grown labs turn the table on foreign Big Pharma in China’s cancer treatment market?

A war is being waged in China’s market for cancer drugs, where home-grown laboratories must strike a delicate balance between social responsibility and cash flow in a long-term strategy to occupy the lion’s share of sales of immuno-oncology treatments.The most ferocious battle front is in the category of immunotherapy drugs called PD-1 and PD-L1 inhibitors, which activate patients’ own immune systems to fight cancer tumours. The payback can be enormous in a market where annual sales of cancer…

Related Articles